Effect of Pneumoperitoneum on Remifentanil Requirements in the Surgical Pleth Index-guided Analgesia

Effect of Pneumoperitoneum on Remifentanil Requirements in the Surgical Pleth Index-guided Analgesia for Laparoscopic Gastrectomy

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03788447

Enrollment

Registered

2018-12-27

Start date

2019-06-04

Completion date

2019-09-05

Last updated

2021-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer

Brief summary

The primary purpose of this study is to investigate the effect of pneumoperitoneum on remifentanil requirements in the surgical pleth index-guided analgesia for laparoscopic gastrectomy.

Interventions

OTHERHigh end-tidal CO2

maintaining of end-tidal CO2 with the range of 40-45 mmHg

OTHERLow CO2 group

maintaining of end-tidal CO2 with the range of 30-35 mmHg

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

19 Years to 85 Years

Healthy volunteers

Inclusion criteria

* laparoscopic gastrectomy under general anesthesia

Exclusion criteria

* atypical hemoglobin disease, infective state, cardiovascular disease, peripheral vascular disease

Design outcomes

Primary

Measure	Time frame	Description
total dose of remifentanil	through study completion, an average of 2 hours	total dose of remifentanil to maintain for surgical pleth index \< 50

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026